CORDIS
EU research results

CORDIS

English EN
EUropean Research initiative to develop Imaging Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic Substances

EUropean Research initiative to develop Imaging Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic Substances

Objective

"We aim develop in-vivo imaging biomarker of multidrug transporter function as a generic tool for the prediction, diagnosis, monitoring and prognosis of major CNS diseases, as well as to provide support and guidance for therapeutic interventions. Multidrug transporters actively transport substrates (including multiple CNS drugs) against concentration gradients across the blood-brain barrier (BBB). Overactivity of these efflux transporters results in inadequate access of CNS drugs to their targets and hampers the build up of adequate tissue levels of these drugs in the brain, greatly limiting their therapeutic efficacy. As such, this ""transporter hypothesis"" of drug resistance is applicable to a broad range of CNS drugs and patients with a variety of CNS diseases who critically depend on these drugs. Efflux transporters may also influence brain elimination of Aβ, the hallmark of Alzheimer’s disease (AD). Impaired multidrug transporter function with reduced clearance of Aβ could lead to accumulation within the extracellular space, contributing to the pathogenesis of AD. We will determine the contribution of multidrug transporters to impaired brain uptake of drugs for the prediction of therapeutic responses, or the contribution of impaired transporter function to reduced clearance of toxic substances for the early in-vivo diagnosis of AD. Circumvention of pharmacoresistance, or increasing clearance, may involve inhibitors of multidrug transporters or sophisticated alternative therapies, but demonstration of overexpression or underactivity of transporter function is an essential and necessary first step. An in-vivo imaging biomarker of multidrug transporter function is essential for identifying altered transporter activity in individual patients. If a relation between overexpression and therapy resistance, or underactivity and AD, can be demonstrated, such a biomarker will provide the means for predicting treatment response, or early diagnosis, in individual patients."
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY COLLEGE LONDON

Address

Gower Street
Wc1e 6bt London

United Kingdom

Activity type

Other

EU Contribution

€ 1 108 027

Administrative Contact

Greta Borg-Carbott (Ms.)

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 184 720

AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH

Austria

EU Contribution

€ 748 267

STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 489 980

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 527 370

HOSPICES CIVILS DE LYON

France

EU Contribution

€ 167 600

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 605 048

THE UNIVERSITY OF LIVERPOOL

United Kingdom

EU Contribution

€ 403 021

UNIVERSITEIT LEIDEN

Netherlands

EU Contribution

€ 376 703

Stichting Epilepsie Instellingen Nederland

Netherlands

EU Contribution

€ 166 675

"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""

Greece

EU Contribution

€ 239 437

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 495 912

VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG

Netherlands

EU Contribution

€ 1 379 453

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 102 637

Project information

Grant agreement ID: 201380

Status

Closed project

  • Start date

    1 February 2008

  • End date

    31 July 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 9 086 523,40

  • EU contribution

    € 6 994 850

Coordinated by:

UNIVERSITY COLLEGE LONDON

United Kingdom